PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayA genome-wide association study conducted in a Swiss psychiatric cohort has identified seven distinct genetic loci associated with psychotropic drug-induced lipid disturbances at a genome-wide significance threshold of P < 5 × 10⁻⁸. The findings highlight both novel drug-specific genetic associations and loci previously linked to total lipid levels in the general population, offering insights toward personalized psychotropic therapy.
Dyslipidemia affects individuals diagnosed with severe mental illness to varying extents, driven in part by medication side effects alongside genetic variations that alter drug-induced lipid shifts. To characterize these genetic contributors, researchers evaluated 829 patients enrolled in the PsyMetab cohort, tracking total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride levels prior to psychotropic treatment and up to one year following administration.
Analysis of total cholesterol changes revealed three significant genetic variants tied to specific psychotropic regimens. The variant rs17313064 G > A was associated with total cholesterol alterations following aripiprazole therapy, rs12543987 G > A showed association following quetiapine treatment, and rs58331124 G > A was linked to total cholesterol changes following combined therapy with quetiapine, olanzapine, and clozapine.
Two separate genetic markers were associated with changes in high-density lipoprotein (HDL) cholesterol levels during psychiatric treatment. Specifically, rs12097296 C > T was linked to HDL-cholesterol changes following lithium administration, while rs10933971 C > T was associated with HDL-cholesterol shifts after treatment with mirtazapine.
The investigators also identified two distinct loci associated with triglyceride fluctuations during treatment. The variant rs10260518 G > T showed a significant association with triglyceride changes following risperidone therapy, whereas the variant rs56286230 T > G was associated with triglyceride changes across patients receiving any psychotropic medication.
To address the absence of a classical replication cohort, the researchers carried out sensitivity analyses examining whether observed associations remained robust across different post-treatment time intervals. Notably, the effect of rs10933971 on HDL-cholesterol remained consistent across diverse patient subsets and observation time frames, supporting the stability of this drug-specific association.
Subject of Research: Genetic variants associated with psychotropic drug-induced lipid disturbances
Article Title: Psychotropic drug-induced lipid disturbances: a genome-wide association study in a Swiss psychiatric cohort
Article References: Jan, M., Delacrétaz, A., Dubath, C., Guex, N., Gamma, F., Preisig, M., Crettol Wavre, S., Ansermot, N., Vandenberghe, F., Grandjean, C., Plessen, K. J., von Gunten, A., Conus, P., Kutalik, Z., & Eap, C. B. (2026). Psychotropic drug-induced lipid disturbances: a genome-wide association study in a Swiss psychiatric cohort. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04419-2
Image Credits: AI Generated
DOI: 10.1038/s41398-026-04419-2
Keywords: psychotropic drugs, dyslipidemia, genome-wide association study, PsyMetab cohort, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, aripiprazole, quetiapine, olanzapine, clozapine, lithium, mirtazapine, risperidone, severe mental illness, rs10933971, personalized psychotropic therapy


54 minutes ago
1




















English (US) ·
French (CA) ·